Life Sciences Compliance in the Middle East: SFDA, EDE, AMAR

On 2 January 2025, the United Arab Emirates dissolved a regulator that had approved medical devices for two decades. Federal Decree-Law No. 38 of 2024 replaced the Ministry of Health and Prevention's device and drug functions with a new federal body, the Emirates Drug Establishment, and by 29 December 2025 the EDE had assumed all 44 of MOHAP's core regulatory services, from marketing authorizations to pharmacovigilance. Then, in February 2026, the EDE introduced a rule that ended the single-distributor model outright: every manufacturer must now appoint more than one authorized agent for each medical product sold in the country.

That single change illustrates what makes the Middle East one of the hardest life sciences markets to track from the outside. Four jurisdictions, four separate regulators, none recognizing each other's approvals. Saudi Arabia's SFDA, the UAE's EDE, Qatar's Ministry of Public Health, and Israel's AMAR each run independent registration systems with different classification logic, different local-representative rules, and different renewal cycles, and 2025 to 2026 has been the busiest stretch of institutional change any of them have had in years.

Here is what actually changed in each jurisdiction and what a compliance team still has to verify by hand.

Which regulator actually controls medical device approval in the UAE now?

The Emirates Drug Establishment, not MOHAP. Federal Decree-Law No. 38 of 2024 came into force on 2 January 2025 and gave the EDE exclusive federal authority over medical products, including devices and in vitro diagnostics, and by 29 December 2025 the EDE had formally taken over all product registration, renewal, variation, import permit, and pharmacovigilance functions that MOHAP previously ran. MOHAP retains jurisdiction only over community and compounding pharmacies and shares limited administrative functions with the EDE.

Certificates issued by MOHAP before the transition remain valid through their original expiry date, but every renewal now goes through the EDE's digital portal at ede.gov.ae, authenticated through UAE PASS, and every new application requires establishment registration with the EDE before a product application can be submitted. The standard product registration fee is 5,000 AED, with a 45-working-day review target, though document preparation, embassy attestation of the Certificate of Free Sale, and establishment registration typically stretch the real timeline to six to twelve months for a first-time entrant. Foreign manufacturers still cannot register directly: a UAE-licensed medical warehouse or marketing office must act as Marketing Authorization Holder.

What does the February 2026 multi-agent rule actually require?

It requires every manufacturer to appoint more than one authorized agent per medical product distributed in the UAE, ending the exclusive single-distributor arrangements that had defined the market for years. The policy is issued under the same Federal Decree-Law No. 38 of 2024 that created the EDE, and it applies going forward to both new market entrants structuring their UAE distribution strategy and existing manufacturers whose current agent agreements assume exclusivity.

For a compliance team, the exposure is contractual as much as regulatory: any distribution agreement signed under the old exclusivity assumption needs review against the new requirement, since a single-agent structure compliant in January 2026 is not automatically compliant later the same year. Manufacturers entering the UAE for the first time should build the multi-agent structure into their channel strategy from the outset rather than retrofitting it after a single distributor is already locked in.

Is Saudi Arabia's MDMA still the fastest route into the Gulf?

For Saudi Arabia itself, yes, and it is also the most useful approval to hold before approaching the rest of the GCC. Since January 2022, the SFDA's GHTF route, which had accepted reference-country approvals like CE marking or US FDA clearance directly, was permanently discontinued, and the Medical Device National Registry listing route for low-risk devices was cancelled the following September. Every device, including Class A, now goes through the MDMA2 Saudi Route: a full Technical File Assessment submitted through the SFDA's GHAD electronic portal, with ISO 13485:2016 certification mandatory for all risk classes.

A foreign manufacturer still needs an SFDA-licensed, Saudi-based Authorized Representative to hold the Establishment License and manage the submission, and the resulting MDMA certificate is valid for three years. There is no mutual recognition agreement between Saudi Arabia and the UAE, so an SFDA MDMA does not exempt a device from full EDE registration and vice versa; the two use structurally different classification systems, IMDRF-based Classes A through D in Saudi Arabia against GHTF-based Classes I through IV in the UAE. What SFDA approval does buy a manufacturer is leverage elsewhere in the Gulf: Kuwait, Bahrain, and Oman all explicitly reference Saudi MDMA approval for a streamlined national review, even though none accepts it as a substitute for their own registration.

How does Qatar's device pathway differ from its Gulf neighbors?

Qatar is the one Gulf jurisdiction without a general pre-market device registration requirement. The Ministry of Public Health's Pharmacy and Drug Control Department splits devices into two tracks: implantable devices require full pre-market registration before any import or sale, while non-implantable devices, the majority of what actually moves through Qatari ports, only need an import permit issued before each individual shipment. Both tracks require the device to already hold approval from a GHTF-recognized reference market such as the FDA, CE marking, or SFDA, and a locally registered Qatari company must act as Authorized Representative since foreign manufacturers cannot interact with the MoPH directly.

That shipment-by-shipment permit model is efficient for routine, low-risk imports but creates a structural blind spot: there is no single national device registry a compliance team can check against, since the record of approval effectively resets with each application. Qatar has been layering additional structure on top of that model, including adoption of the GSO standard QS GSO ISO/TR 20416:2024 on post-market surveillance for device manufacturers, pushing its vigilance expectations closer to its neighbors even without a comparable registration database.

What changed in Israel's medical device registration system?

AMAR, the Medical Device Division of Israel's Ministry of Health, finished rolling out the tiered registration scheme it introduced in August 2023, and by 2025 to 2026 all three routes, Declaration, Fast-Track, and Standard, were fully operational. Class I devices get immediate registration under the Declaration route, and Class II devices with existing FDA or EU MDR approval can move through 45 or 60-day Fast-Track pathways depending on risk. AMAR published REG-2024/03, updated submission guidance, effective January 2025, and REG-2024/07 covering renewal and modification requirements the same year.

The heavier obligation lands on the Israel Registration Holder, the mandatory local agent every foreign manufacturer must appoint, which functions similarly to an EU Authorized Representative. Under the 2025 to 2026 guidelines, the IRH must prepare periodic post-marketing reports for registration renewal, and, distinctively among the region's regulators, actively monitor regulatory restrictions imposed by foreign authorities worldwide and report to the Minister of Health any that could affect the device's safety profile in Israel. High-risk device and IVD renewals cannot proceed without that report attached. Manufacturers relying on a distributor to double as IRH face a real risk: if the commercial relationship ends, the registration itself can become a bargaining chip, since market access ties to whichever entity holds the IRH role, not to the manufacturer directly.

Why does a Saudi clinical trial approval not transfer anywhere else in the region?

Because clinical trial oversight, like device registration, runs on entirely separate national tracks with no mutual recognition. The SFDA reissued its clinical trials guideline as Version 4.0 on 28 June 2026, confirming that early-phase trials, Phase I, II, and III, still require SFDA approval before initiation through the Saudi Clinical Trial Registry, while Phase IV studies only need notification within 20 working days of local Institutional Review Board approval. Sponsors without a Saudi legal entity must route submissions through an SFDA-licensed Saudi Contract Research Organization, and the evaluation fee remains 15,000 Saudi riyals, waived for government-sponsored, unsponsored, and Phase IV trials.

Suspected unexpected serious adverse reactions must reach the SFDA within 15 days for both local and global cases, and essential trial documents must be retained for at least 15 years after completion, one of the longer retention windows in any jurisdiction Obsidian tracks. None of that framework carries over to a trial run in the UAE, Qatar, or Israel: each maintains its own ethics committee structure, its own adverse-event clock, and its own sponsor documentation rules, so a multi-country Gulf trial program means building four separate compliance files, not one regional dossier.

How should a life sciences compliance team monitor four regulators without four separate subscriptions?

The practical fix is treating the SFDA, the EDE, Qatar's MoPH, and Israel's AMAR as four distinct tier-0 sources rather than one generic "Middle East" bucket, since a calendar that flattens them together will miss exactly the kind of institutional restructuring the UAE went through in 2025 and 2026. Obsidian tracks MDR, IVDR, FDA 21 CFR, ISO 13485, and the region's national frameworks with per-jurisdiction monitoring, so an EDE policy change or an SFDA guideline reissue reaches the right compliance owner the week it publishes. See how the coverage is structured on the monitoring page.

For teams juggling MDR, IVDR, and four separate Middle East registration systems at once, Obsidian's AI companion gives a fast, source-linked answer to a question like whether a distributor agreement still satisfies the UAE's post-February 2026 multi-agent rule, drawing on the same verified records referenced throughout this article, never as a substitute for legal counsel. Teams building their own internal tooling can pull that same data through the MCP, and organizations evaluating coverage can start with plans scoped to the Gulf and Israel.

What should a Middle East compliance team check this quarter?

Confirm every UAE distribution agreement complies with the February 2026 multi-agent rule before a single-agent structure gets challenged at renewal. Verify that any device sold in both Saudi Arabia and the UAE carries two live, independently maintained registrations, since no mutual recognition agreement exists between the SFDA and the EDE. For Qatar, check that non-implantable shipments have a current import permit rather than assuming a prior approval still applies, and for Israel, confirm the Israel Registration Holder is actually filing the periodic reports AMAR now requires for renewal.

None of that requires guessing which regulator moves next. Obsidian's per-jurisdiction alerts exist so that an EDE policy notice or a reissued SFDA guideline reaches your team the week it is published, not the week a shipment gets held at customs because of it.